The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of 6 mg melatonin daily for 1 week
preoperatively to 12 weeks postoperatively on depressive symptoms, anxiety, cognitive
function and sleep disturbances in breast cancer patients. Furthermore the investigators will
examine whether a specific clock-gene (HPER3) is correlated with an increased risk of
depression, sleep disturbances or cognitive dysfunction.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Melissa Voigt Hansen
Collaborators:
Pharma Nord Rigshospitalet, Denmark University of Copenhagen